Report DMCA Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelo
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.